Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P19086
UPID:
GNAZ_HUMAN
Alternative names:
G(x) alpha chain; Gz-alpha
Alternative UPACC:
P19086; B2R6C1; Q4QRJ6
Background:
The Guanine nucleotide-binding protein G(z) subunit alpha, also known as G(x) alpha chain or Gz-alpha, plays a pivotal role in cellular signaling. As a member of the G proteins, it acts as a crucial modulator or transducer in various transmembrane signaling systems, influencing numerous physiological processes.
Therapeutic significance:
Understanding the role of Guanine nucleotide-binding protein G(z) subunit alpha could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways underscores its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.